Use of ACE-inhibitors in Serbia in 2009 and 2010

Dajana Peric,Aleksandar Knezevic,Boris Milijasevic,Dragana Milijasevic,Natasa Tomic,Nina Bukumirovic

doi:10.5937/hpimj1403122p

Dajana Peric, Aleksandar Knezevic + Show 4 more

Open Access

https://doi.org/10.5937/hpimj1403122p

Copy DOI

Abstract

Introduction Cardiovascular diseases (CVD) are the most frequent cause of morbidity and mortality in many countries as well as in our country. That explains why medications for the treatment of CVD are the most used group of drugs. The aim of this study was to analyze the consumption of ACE-inhibitors in Serbia and Norway during 2009 and 2010. Material and methods The data about the use of ACE-inhibitors in Serbia and Norway in 2009 and 2010 were taken from the Agency for Drugs and Medical Devices of the Republic of Serbia and from the site of Norwegian Institute of Public Health. Results Use of drugs of first choice in the treatment of hypertension in Serbia was very uneven, where the consumption of ACE-inhibitors was dominant. Opposed to this condition, the consumption of the first choice antihypertensive drugs was very balanced in Norway. During both analyzed years large part of consumption of ACE-inhibitors was taken by more expensive drugs in Serbia, as fosinopril, cilazapril and quinapril. In Norway in the observed period, dominated the consumption of cheaper drugs such as enalapril and ramipril. The situation is similar when it comes to fixed combination of diuretics and ACE-inhibitors. In Norway dominated the fixed combination of diuretics and cheaper ACE-inhibitors like enalapril and lisinopril. However, in Serbia, we have large consumption fixed combinations of diuretics with expensive ACE-inhibitors, such as cilazapril and fosinopril. Conclusions In both countries, ACE-inhibitors and their fixed combination with diuretics are most frequently used drugs within the group of drugs which is used for treatment of CVD in Serbia in 2009 and 2010. The amount and structure of the utilized ACE-inhibitors in Serbia is different from the amount and structure of the utilized ACE inhibitors in Norway. From pharmacoeconomic point of view, high consumption of expensive ACE-inhibitors (plain and fixed combination with diuretics) in 2009 and 2010 in Serbia resulted in the higher spending of funds.

Highlights

Cardiovascular disease (CVD) and kidney disease are the most common cause of morbidity and mortality in industrialized countries [1]
It is understandable why drugs which are in use for the treatment of cardiovascular disease are the most frequently used group of drugs
In Norway, consumption of drugs for the treatment of cardiovascular disease observed in this two years was lower than in Serbia, amounting to about 31%, without trend of increasing consumption

Summary

Introduction

Cardiovascular disease (CVD) and kidney disease are the most common cause of morbidity and mortality in industrialized countries [1]. In 2008, the rate of mortality from CVD in Serbia stood at 55.8% which ranks Serbia among the countries with the highest cardiovascular mortality [2]. It is understandable why drugs which are in use for the treatment of cardiovascular disease (group C according to ATC classification) are the most frequently used group of drugs. Consumption of drugs from the C group has steadily increased in Serbia. In relation to all drugs of C group, in the world, and in our country angiotensin converting enzyme inhibitors (ACE-inhibitors), drugs used in treatment of hypertension and cardiac insufficiency, occupy an important place [4, 5, 6]

Objectives

Methods

Results

Discussion

Conclusion